HIV-1 entry inhibition by small-molecule CCR5 antagonists: A combined molecular modeling and mutant study using a high-throughput assay

Virology

Volumn 413, Issue 2, 2011, Pages 231-243

  Labrecque, Jean ^a   Metz, Markus ^a   Lau, Gloria ^a   Darkes, Marilyn C ^a   Wong, Rebecca S Y ^a   Bogucki, David ^a   Carpenter, Bryon ^a   Chen, Gang ^a   Li, Tongshuang ^a   Nan, Susan ^a   Schols, Dominique ^b   Bridger, Gary J ^a   Fricker, Simon P ^a   Skerlj, Renato T ^a  

^a GENZYME CORPORATION   (United States)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Antifusogenic assay; Aplaviroc; Binding site characterization; CCR5; HIV 1; Homology modeling; Maraviroc; Mutagenesis; Small molecule antagonists; Vicriviroc

Indexed keywords

4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; ALLYL [1 [4 (BENZENESULFONYL METHYL AMINO) 3 METHYL 3 PHENYL BUTYL]PIPERIDIN 4 YL]CARBAMIC ACID 4 NITRO BENZYL ESTER; APLAVIROC; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; UNCLASSIFIED DRUG; VICRIVIROC;

ANTIFUSOGENIC ASSAY; ANTIVIRAL ACTIVITY; ARTICLE; ASSAY; ASTROCYTOMA; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG BINDING SITE; DRUG DESIGN; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYDROPHOBICITY; MOLECULAR INTERACTION; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VALIDATION PROCESS; VIRUS CELL INTERACTION;

HIGH-THROUGHPUT SCREENING ASSAYS; HIV FUSION INHIBITORS; HIV-1; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; MUTATION; PROTEIN CONFORMATION; RECEPTORS, CCR5; REPRODUCIBILITY OF RESULTS; STEREOISOMERISM; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79954630072     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.02.016     Document Type: Article

References (63)

1. Allen S.J., Crown S.E., Handel T.M. Chemokine: receptor, structure, interactions, and antagonism. Annu. Rev. Immunol. 2007, 25:787-820.
2. Arias A.D., Navenot J.-M., Zhang Z.-B., Broach J., Peiper S.C. Constitutive activation of CCR5 and CCR2 induced by conformational changes in the conserved TXP motif in transmembrane helix 2. J. Biol. Chem. 2003, 278:36513-36521.
3. Ballesteros J.A., Palczewski K. G protein-coupled receptor drug discovery: implications from the crystal structure of rhodopsin. Curr. Opin. Drug Discov. Devel. 2001, 4:561-574.
4. Barber C.G. CCR5 antagonists for the treatment of HIV. Curr. Opin. Investig. Drugs 2004, 5:851-861.
5. Berger E.A., Doms R.W., Fenyoe E.-M., Korber B.T.M., Littman D.R., Moore J.P., Sattentau Q.J., Schuitenmaker H., Sodroski J., Weiss R.A. A new classification for HIV-1. Nature 1998, 391:240.
6. Berkhout T.A., Blaney F.E., Bridges A.M., Cooper D.G., Forbes I.T., Gribble A.D., Groot P.H.E., Hardy A., Ife R.J., Kaur R., Moores K.E., Shillito H., Willetts J., Witherington J. CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach. J. Med. Chem. 2003, 46:4070-4086.
7. Bertini R., Allegretti M., Bizarri C., Moriconi A., Locati M., Zampella G., Cervellera M.N., Di Cioccio V., Cesta M.C., Galliera E., Martinez F.O., Di Bitondo R., Troiani G., Sabbatini V., D'Anniballe G., Anacardio R., Cutrin J.C., Cavalieri B., Mainiero F., Strippoli R., Villa P., Di Girolamo M., Martin F., Gentile M., Santoni A., Corda D., Poli G., Mantovani A., Ghezzi P., Colotta F. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. PNAS 2004, 101:11791-11796.
8. Billick E., Seibert C., Pugach P., Ketas T., Trkola A., Endres M.J., Murgolo N.J., Coates E., Reyes G.R., Baroudy B.M., Sakmar T.P., Moore J.P., Kuhmann S.E. The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors. J. Virol. 2004, 78:4134-4144.
9. Blanpain C., Doranz B.J., Bondue A., Govaerts C., De Leener A., Vassart G., Doms R.W., Proudfoot A., Parmentier M. The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. J. Biol. Chem. 2003, 278:5179-5187.
10. Castonguay L.A., Weng Y., Adolfsen W., Di Salvo J., Kilburn R., Caldwell C.G., Daugherty B.L., Finke P.E., Hale J.J., Lynch C.L., Mills S.G., MacCoss M., Springer M.S., DeMartino J.A. Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket. Biochemistry 2003, 42:1544-1550.
11. Crabb C. GlaxoSmithKline ends aplaviroc trials. AIDS 2006, 20:641.
12. de Mendonca F.L., da Fonseca P.C.A., Phillips R.M., Saldanha J.W., Williams T.J., Pease J.E. Site-directed mutagenesis of CC chemokine receptor 1 reveals the mechanism of action of UCB 35625, a small molecule chemokine receptor antagonist. J. Biol. Chem. 2005, 280:4808-4816.
13. Dragic T. An overview of the determinants of CCR5 and CXCR4 co-receptor function. J. Gen. Virol. 2001, 82:1807-1814.
14. Dragic T., Trkola A., Thompson D.A., Cormier E.G., Kajumo F.A., Maxwell E., Lin S.W., Ying W., Smith O.S., Sakmar T.P., Moore J.P. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl Acad. Sci. USA 2000, 97:5639-5644.
15. Faetkenheuer G., Pozniak A.L., Johnson M.A., Plettenberg A., Staszewski S., Hoepelman A.I.M., Saag M.S., Goebel F.D., Rockstock J.K., Dezube B.J., Jenkins T.M., Medhurst C., Sullivan J.F., Ridgway C., Abel S., James I.T., Youle M., van der Ryst E. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 2005, 11:1170-1171.
16. Finke P.E., Oates B., Mills S.G., MacCoss M., Malkowitz L., Springer M.S., Gould S.L., DeMartino J.A., Carella A., Carver G., Holmes K., Danzeisen R., Kessler J., Lineberger J., Miller M., Schleif W.A., Emini E.A. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes. Bioorg. Med. Chem. Lett. 2001, 11:2475-2479.
17. Gerlach L.O., Skerlj R.T., Bridger G.J., Schwartz T.W. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J. Biol. Chem. 2001, 276:14153-14160.
18. Govaerts C., Bondue A., Springael J.-Y., Olivella M., Deupi X., Le Poul E., Wodak S.J., Parmentier M., Pardo L., Blampain C. Activation of CCR5 by chemokines involves an aromatic cluster between transmembrane helices 2 and 3. J. Biol. Chem. 2003, 278:1892-1903.
19. Habashita H., Kokubu M., Hamano S., Hamanaka N., Toda M., Shibayama S., Tada H., Sagawa K., Fukushima D., Maeda K., Mituya H. Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists. J. Med. Chem. 2006, 49:4140-4152.
20. Kazmierki W.M., Peckham J.P., Duan M., Kenakin T.P., Jenkinson S., Gudmundson K.S., Piscitelli S.C., Feldman P.L. Recent progress in the discovery of new CCR5 and CXCR4 chemokine receptor antagonists as inhibitors of HIV-1 entry. Part 2. Curr. Med. Chem. Anti Infect. Agents 2005, 4:133-152.
21. Kenakin T. G-protein coupled receptors as allosteric machines. Receptors Channels 2004, 10:51-60.
22. Kenakin T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat. Rev. Drug Discov. 2005, 4:919-927.
23. Klibanov O.M. Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection. Curr. Opin. Investig. Drugs 2009, 10:845-859.
24. Kondru R., Zhang J., Ji C., Mirzadegan T., Rotstein D., Sunkurati S., Dioszegi M. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol. Pharm. 2008, 73:789-800.
25. Kromdijk W., Hiutema A.D., Mulder J.W. Treatment of HIV infection with CCR5 antagonist maraviroc. Expert Opin. Pharmacother. 2010, 11:1215-1223.
26. Lalezari J., Thompson M., Kumar P., Piliero P., Davey R., Patterson K., Shachoy-Clark A., Adkison K., Demarest J., Lou Y., Berrey M., Piscitelli S. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS 2005, 19:1443-1447.
27. Lenz J.C.C., Rockstroh J.K. Vicriviroc, a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties, promises and challenges. Expert Opin. Drug Metab. Toxicol. 2010, 6:1139-1150.
28. Lusso P. HIV and the chemokine system: 10years later. EMBO J. 2006, 25:447-456.
29. Maeda K., Nakata H., Koh Y., Miyakawa T., Ogata H., Takaoka Y., Shibayama S., Sagawa K., Fukushima D., Moravek J., Koyanagi Y., Mitsuya H. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J. Virol. 2004, 78:8654-8662.
30. Maeda K., Das D., Ogata-Aoki H., Nakata H., Miyakawa T., Tojo Y., Norman R., Takaoka Y., Ding J., Arnold E., Mitsuya H. Structural and molecular interactions of CCR5 inhibitors with CCR5. J. Biol. Chem. 2006, 281:12688-12698.
31. Mansfield R., Able S., Griffin P., Irvine B., James I., Macartney M., Miller K., Mills J., Napier C., Navratilova I., Perros M., Rickett G., Root H., van der Ryst E., Westby M., Dorr P. CCR5 pharmacology methodologies and associated applications. Methods Enzymol. 2009, 460:17-55.
32. Markovic I. Advances in HIV-1 entry inhibitors: strategies to interfere with receptor and coreceptor engagement. Curr. Pharm. Des. 2006, 12:1105-1119.
33. Marozsan A.J., Kuhmann S.E., Morgan T., Herrera C., Rivera-Troche E., Xu S., Baroudy B.M., Strizki J., Moore J.P. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 2005, 338:182-199.
34. Merck Accessed on February 16, 2011. http://www.merck.com/newsroom/news-release-archive/research-and-development/2010_0217.html.
35. Mirzadegan T., Diehl F., Ebi B., Bhaktra S., Polsky I., McCarley D., Mulkins M., Weatherhead G.S., Lapierre J.-M., Dankwardt J., Morgans D., Wilhelm R., Jarnagin K. Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists. J. Biol. Chem. 2000, 275:25562-25571.
36. Nadler J.P., Phillips M.C. New HIV drugs in development. Curr. Infect. Dis. Rep. 2005, 7:221-226.
37. Nishikawa M., Takashima K., Nishi T., Furuta R.A., Kanzaki N., Yamamoto Y., Fujisawa J.-I. Analysis of binding sites for the new small-molecule CCR5 antagonists TAK-220 on human CCR5. Antimicrob. Agents Chemother. 2005, 49:4708-4715.
38. Nishizawa R., Nishiyama T., Hisaichi K., Matsunaga N., Minamoto C., Habashita H., Takaoka Y., Toda M., Shibayama S., Tada H., Sagawa Y., Fukushima D., Maeda K., Mituya H. Spirodiketopiperazine-based CCR5 antagonists: lead optimization from biologically active metabolite. Bioorg. Med. Chem. Lett. 2007, 17:727-731.
39. Nishizawa R., Nishiyama T., Hisaichi K., Hirai K., Habashita H., Takaoka Y., Tada H., Sagawa K., Shibayama S., Maeda K., Mitsuya H., Nakai H., Fukushima D., Toda M. Discovery of orally available spirodiketopiperazine-based CCR5 antagonists. Bioorg. Med. Chem. 2010, 18:5208-5223.
40. Nishizawa R., Nishiyama T., Hisaichi K., Hirai K., Habashita H., Takaoka Y., Tada H., Sagawa K., Shibayama S., Maeda K., Mitsuya H., Nakai H., Fukushima D., Toda M. Spirodiketopiperazine-based CCR5 antagonists: improvement of their pharmacokinetic profiles. Bioorg. Med. Chem. Lett. 2010, 20:763-766.
41. Oliveira L., Hulsen T., Hulsik D.L., Paiva A.C.M., Vriend G. Heavier-than-air flying machines are impossible. FEBS Lett. 2004, 564:269-273.
42. Onuffer J.J., Horuk R. Chemokine, chemokine receptors, and small molecule antagonists: recent developments. Trends Pharmacol. Sci. 2002, 23:459-467.
43. Palani A., Tagat J.R. Disocvery and development of small-molecule chemokine coreceptor CCR5 antagonists. J. Med. Chem. 2006, 49:2851-2857.
44. Palani A., Shairo S., Josien H., Bara T., Clader J.W., Greenlee W.J., Cox K., Stritzki J.M., Baroudy B.M. Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity. J. Med. Chem. 2002, 45:3143-3160.
45. Paterlini M.G. Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity. Biophys. J. 2002, 83:3012-3031.
46. Perry C.M. Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection. Drugs 2010, 70:1189-1213.
47. Price D.A., Gayton S., Selby M.D., Ahman J., Haycock-Lewandowski S., Stammen B.L., Warren A. Initial synthesis of UK-427,857 (Maraviroc). Tetrahedron Lett. 2005, 46:5005-5007.
48. Rosenkilde M.M., Gerlach L.O., Jacobsen J.S., Skerlj R.T., Bridger G.J., Schwartz T.W. Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor. J. Biol. Chem. 2004, 279:3033-3041.
49. Sayana S., Khanlou H. Maraviroc: a new CCR5 antagonist. Expert Rev. Anti Infect. Ther. 2009, 7:9-19.
50. Seibert C., Ying W., Gavrilov S., Tsamis F., Kuhmann S.E., Palani A., Tagat J.R., Clader J.W., McCombie S.W., Baroudy B.M., Smith S.O., Dragic T., Moore J.P., Sakmar T.P. Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology 2006, 349:41-54.
51. Shiraishi M., Aramaki T., Seto M., Imoto H., Nishikawa Y., Kanzaki N., Okamoto M., Sawada H., Nishimura O., Baba M., Fujino M. Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. J. Med. Chem. 2000, 43:2049-2063.
52. Shuermann D., Faetkenheuer G., Reynes J., Michelet C., Raffi F., van Lier J., Caceres M., Keung A., Sansone-Parsons A., Dunkle L.M., Hoffmann C. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 2007, 21:1293-1299.
53. Strizki J.M., Tremblay C., Xu S., Wojcik L., Wagner N., Gonsiorek W., Hipkin R.W., Chou C.-C., Pugliese-Sivo C., Xiao Y., Tagat J.R., Cox K., Priestley T., Sorota S., Huang W., Hirsch M., Reyes G.R., Baroudy B.M. Discovery and characterization of vicriviroc (SCH 417690) a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2005, 49:4911-4919.
54. Stupple P.A., Batchelor D.V., Corless M., Dorr P.K., Ellis D., Fenwick D.R., Galan S.R.G., Jones R.M., Mason H.J., Middleton D.S., Perros M., Perruccio F., Platts M.Y., Pryde D.C., Rodrigues D., Smith N.N., Stephenson P.T., Webster R., Westby M., Wood A. An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobuturyl-2-methyl-4,5,6,7-tetrahydo-1H-imidazo[4,5-c]pyridine-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798). J. Med. Chem. 2011, 54:67-77.
55. Tagat J.R., McCombie S.W., Steensma R.W., Lin S.-I., Nazareno D.V., Baroudy B., Vantuno N., Xu S., Liu J. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element. Bioorg. Med. Chem. Lett. 2001, 11:2143-2146.
56. Teller D.C., Okada T., Behnke C.A., Palczewski K., Stenkamp R.E. Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). Biochemistry 2001, 40:7761-7772.
57. Tilton J.C., Wilen C.B., Didigu C.A., Sinha R., Harrison J.E., Agrawal-Gamse C., Henning E.A., Bushmannn F.D., Martin J.N., Deeks S.G., Doms R.W. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J. Virol. 2010, 84:10863-10876.
58. Trent J.O., Wang Z.-X., Murray J.L., Shao W., Tamamura H., Nobutaka F., Peiper S.C. Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists. J. Biol. Chem. 2003, 278:47136-47144.
59. Tsamis F., Gavrilov S., Kajumo F., Seibert C., Kuhmann S., Ketas T., Trkola A., Palani A., Clader J.W., Tagat J.R., McCombie S., Baroudy B., Moore J.P., Sakmar T.P., Dragic T. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency type 1 entry. J. Virol. 2003, 77:5201-5208.
60. Vaidehi N., Schlyer S., Trabanino R.J., Floriano W.B., Abrol R., Sharma S., Kochanny M., Koovakat S., Dunning L., Liang L., Fox J.M., de Medonca F.L., Pease J.E., Goddard W.A., Horuk R. Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation. J. Biol. Chem. 2006, 281:27613-27620.
61. Watson C., Jenkinson S., Kazmierski W., Kenakin T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol. Pharmacol. 2005, 67:1268-1282.
62. Wilkin T.J., Su Z., Krambrink A., Long J., Greaves W., Gross R., Huges M.D., Flexner C., Skolnik P.R., Coakley E., Godfrey C., Hirsch M., Kuritzkes D.R., Gulick R.M. Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients. J. Acquir. Immune Defic. Syndr. 2010, 15:470-476.
63. Wong R.S.Y., Bodard V., Metz M., Labrecque J., Bridger G., Fricker S.P. Comparison of the potential multiple binding modes of bicyclam, monocyclam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors. Mol. Pharm. 2008, 74:1485-1495.